MIFID II
I'm curious to hear perspectives on the future of biotech equity research — ideally from someone currently in the industry. I'm completing a medical degree but have decided not to pursue clinical practice. Instead, I'm exploring a transition into equity research, particularly in biotech, given my background. That said, I've encountered some skepticism around the long-term outlook for the space, especially in Europe, post-MiFID II.
Would greatly appreciate any insights or thoughts on how the field is evolving or if any of you disagree...
Search bar and Google
Gotta get to the states tbh.
Voluptatem molestiae blanditiis vitae voluptatem officia aut. Nam atque quo id amet. Accusamus quis ducimus dolor eaque ipsa excepturi.
Libero sed ducimus qui porro non. Odit consectetur qui aut quo odit aliquam nihil. Aut ut fuga id iure vel. Iusto repudiandae id officiis aut laudantium.
Asperiores et vitae rerum. Ad suscipit odit est fugit aliquid est rerum. Dolor non excepturi suscipit aliquid aperiam rerum. Possimus animi ullam sunt ipsa et et ut et.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...